Bristol-Myers Squibb Company logo
Bristol-Myers Squibb Company (BMY)
Compare

Bristol-Myers Squibb Company (BMY) Price/FCF Ratio: 9.76

Is Bristol-Myers Squibb Company’s Price/FCF ratio high or low?

Bristol-Myers Squibb Company's Price/FCF ratio of 9.76 is in line with its 5-year average of 9.56, around the middle of its 5-year range (5.96–13.69).

25.94% above its 12-month average of 7.75.

BMY Price/FCF Ratio Chart

BMY Price/FCF Ratio
9.76+24.97% 1Y
Zoom

BMY Average Price/FCF Ratio Chart

BMY Current vs Average Price/FCF Ratio Chart

BMY Price/FCF Ratio Metrics

PRICE/FCF RATIO

9.76

PRICE/FCF RATIO AVG TTM

7.75

PRICE/FCF RATIO AVG 3Y

8.44

PRICE/FCF RATIO AVG 5Y

9.56

PRICE/FCF RATIO AVG 10Y

53.69

PRICE/FCF RATIO AVG 15Y

65.02

PRICE/FCF RATIO AVG 20Y

54.94

CURRENT VS TTM AVG

+25.94%

CURRENT VS 3Y AVG

+15.70%

CURRENT VS 5Y AVG

+2.12%

CURRENT VS 10Y AVG

-81.82%

CURRENT VS 15Y AVG

-84.99%

CURRENT VS 20Y AVG

-82.24%

BMY Competitors' Price/FCF Ratio

NAMEMARKET CAPPRICE/FCF RATIOTTM3Y5Y
Bristol-Myers Squibb Company (BMY)$116.13B9.767.758.449.56
Vertex Pharmaceuticals Incorporated (VRTX)$110.59B30.3833.0630.0727.15
Danaher Corporation (DHR)$126.39B24.6829.0229.6928.00
CVS Health Corporation (CVS)$126.70B16.9615.7614.2611.77
Medtronic plc (MDT)$102.72B19.0522.3422.5623.73
Intuitive Surgical, Inc. (ISRG)$144.79B52.3081.09163.31127.32
Elevance Health Inc. (ELV)$86.47B13.8218.0141.2730.19
Pfizer Inc. (PFE)$149.61B15.8813.9119.4316.06
Cigna Corporation (CI)$77.92B10.2012.9211.5011.57
Abbott Laboratories (ABT)$155.75B21.2029.7233.5029.77

Free Cash Flow Valuation

P/FCF Ratio

9.8

FCF Yield

10.25%

Bristol-Myers Squibb Company Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Bristol-Myers Squibb Company Price/FCF Ratio FAQ

What is the Price/FCF ratio for Bristol-Myers Squibb Company (BMY)?
The Price/FCF ratio for BMY stock is 9.76.
Is Bristol-Myers Squibb Company's Price/FCF ratio high or low?
Bristol-Myers Squibb Company's Price/FCF ratio of 9.76 is in line with its 5-year average of 9.56, around the middle of its 5-year range (5.96–13.69).
What is the TTM average Price/FCF ratio for Bristol-Myers Squibb Company (BMY)?
The TTM average Price/FCF ratio for BMY stock is 7.75.
What is the 3Y average Price/FCF ratio for Bristol-Myers Squibb Company (BMY)?
The 3Y average Price/FCF ratio for BMY stock is 8.44.
What is the 5Y average Price/FCF ratio for Bristol-Myers Squibb Company (BMY)?
The 5Y average Price/FCF ratio for BMY stock is 9.56.
What is the 10Y average Price/FCF ratio for Bristol-Myers Squibb Company (BMY)?
The 10Y average Price/FCF ratio for BMY stock is 53.69.
What is the 15Y average Price/FCF ratio for Bristol-Myers Squibb Company (BMY)?
The 15Y average Price/FCF ratio for BMY stock is 65.02.
What is the 20Y average Price/FCF ratio for Bristol-Myers Squibb Company (BMY)?
The 20Y average Price/FCF ratio for BMY stock is 54.94.

Bristol-Myers Squibb Company Price/FCF Ratio History

DATEPRICE/FCF RATIO
2026-06-119.76
2026-06-109.54
2026-06-099.69
2026-06-089.54
2026-06-059.83
2026-06-049.71
2026-06-039.39
2026-06-029.35
2026-06-019.43
2026-05-299.81
2026-05-289.77
2026-05-279.87
2026-05-269.96
2026-05-2210.20
2026-05-2110.22
2026-05-2010.05
2026-05-1910.01
2026-05-189.83
2026-05-159.78
2026-05-149.74
2026-05-139.68
2026-05-129.69
2026-05-119.55
2026-05-089.64
2026-05-079.65
2026-05-069.70
2026-05-059.77
2026-05-049.85
2026-05-019.99
2026-04-3010.40
2026-04-299.15
2026-04-289.26
2026-04-279.18
2026-04-249.33
2026-04-239.38
2026-04-229.34
2026-04-219.44
2026-04-209.40
2026-04-179.56
2026-04-169.37
2026-04-159.20
2026-04-149.23
2026-04-139.23
2026-04-109.31
2026-04-099.45
2026-04-089.41
2026-04-079.16
2026-04-069.43
2026-04-029.47
2026-04-019.81
2026-03-319.64
2026-03-309.49
2026-03-279.30
2026-03-269.44
2026-03-259.37
2026-03-249.12
2026-03-239.06
2026-03-209.13
2026-03-199.23
2026-03-189.43
2026-03-179.49
2026-03-169.49
2026-03-139.39
2026-03-129.37
2026-03-119.53
2026-03-109.55
2026-03-099.63
2026-03-069.58
2026-03-059.65
2026-03-049.90
2026-03-039.73
2026-03-029.91
2026-02-279.91
2026-02-269.71
2026-02-259.74
2026-02-249.79
2026-02-239.73
2026-02-209.64
2026-02-199.58
2026-02-189.49
2026-02-179.59
2026-02-139.65
2026-02-129.51
2026-02-119.52
2026-02-108.11
2026-02-098.09
2026-02-068.26
2026-02-057.93
2026-02-047.67
2026-02-037.46
2026-02-027.44
2026-01-307.33
2026-01-297.23
2026-01-287.27
2026-01-277.40
2026-01-267.27
2026-01-237.28
2026-01-227.32
2026-01-217.26
2026-01-207.22
2026-01-167.36
2026-01-157.54
2026-01-147.59
2026-01-137.45
2026-01-127.43
2026-01-097.44
2026-01-087.44
2026-01-077.55
2026-01-067.25
2026-01-057.07
2026-01-027.12
2025-12-317.18
2025-12-307.22
2025-12-297.21
2025-12-267.28
2025-12-247.29
2025-12-237.23
2025-12-227.28
2025-12-197.22
2025-12-187.10
2025-12-177.13
2025-12-167.22
2025-12-157.23
2025-12-126.98
2025-12-116.82
2025-12-106.82
2025-12-096.75
2025-12-086.88
2025-12-056.95
2025-12-046.92
2025-12-036.79
2025-12-026.43
2025-12-016.55
2025-11-286.55
2025-11-266.56
2025-11-256.53
2025-11-246.36
2025-11-216.16
2025-11-206.12
2025-11-196.10
2025-11-186.27
2025-11-176.23
2025-11-146.21
2025-11-136.48
2025-11-126.54
2025-11-116.49
2025-11-106.29
2025-11-076.22
2025-11-066.21
2025-11-056.19
2025-11-046.07
2025-11-036.13
2025-10-316.14
2025-10-306.08
2025-10-295.96
2025-10-285.99
2025-10-276.07
2025-10-246.13
2025-10-236.13
2025-10-226.21
2025-10-216.23
2025-10-206.09
2025-10-176.10
2025-10-166.07
2025-10-156.10
2025-10-146.12
2025-10-136.09
2025-10-106.15
2025-10-096.25
2025-10-086.23
2025-10-076.24
2025-10-066.31
2025-10-036.35
2025-10-026.39
2025-10-016.63
2025-09-306.30
2025-09-296.17
2025-09-266.17
2025-09-256.07
2025-09-246.17
2025-09-236.28
2025-09-226.29
2025-09-196.29
2025-09-186.37
2025-09-176.45
2025-09-166.48
2025-09-156.48
2025-09-126.46
2025-09-116.65
2025-09-106.59
2025-09-096.60
2025-09-086.53
2025-09-056.59
2025-09-046.53
2025-09-036.64
2025-09-026.63
2025-08-296.60
2025-08-286.55
2025-08-276.66
2025-08-266.60
2025-08-256.59
2025-08-226.70
2025-08-216.77
2025-08-206.75
2025-08-196.76
2025-08-186.74
2025-08-156.77
2025-08-146.68
2025-08-136.69
2025-08-126.51
2025-08-116.42
2025-08-086.42
2025-08-076.34
2025-08-066.27
2025-08-056.41
2025-08-046.35
2025-08-016.18
2025-07-316.05
2025-07-307.16
2025-07-297.29
2025-07-287.40
2025-07-257.54
2025-07-247.62
2025-07-237.62
2025-07-227.47
2025-07-217.27
2025-07-187.37
2025-07-177.48
2025-07-167.34
2025-07-157.23
2025-07-147.37
2025-07-117.29
2025-07-107.55
2025-07-097.42
2025-07-087.32
2025-07-077.24
2025-07-037.30
2025-07-027.41
2025-07-017.40
2025-06-307.21
2025-06-277.21
2025-06-267.26
2025-06-257.27
2025-06-247.32
2025-06-237.30
2025-06-207.29
2025-06-187.29
2025-06-177.35
2025-06-167.57
2025-06-137.74
2025-06-127.89
2025-06-117.81
2025-06-107.78
2025-06-097.63
2025-06-067.54
2025-06-057.45
2025-06-047.46
2025-06-037.49
2025-06-027.59
2025-05-307.52

Showing the most recent 260 of 5,032 data points. The chart above shows the full history.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ
34,100 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher S. Boerner